entity

ALX

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALX: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

20Connections
0Hypotheses
1Analyses
17Outgoing
3Incoming

Wiki Pages (13)

Knowledge base pages for this entity

Section 188: Advanced Lipidomics and Membrane Therapy in CBS/PSP

therapeutic · 2860 words

versant-ventures

institution · 2686 words

Specialized Pro-Resolving Mediator (SPM) Therapies for Neurodegeneration

therapeutic · 2461 words

Blarcamesine (ALX-001)

therapeutic · 2127 words

Specialized Pro-Resolving Mediator (SPM) Therapy for Neurodegeneration

therapeutic · 1803 words

Outgoing (17)

TargetRelationTypeStr
Anti-inflammatory Responsemediatesprocess0.87
ANXA1bindsprotein0.85
pulmonary endothelial glycocalyxregulatesprocess0.80
Annexin A1interacts_withprotein0.80
AMPK-mTOR Pathwayactivatespathway0.80

Incoming (3)

SourceRelationTypeStr
PCTR1activatescompound0.80
rapamycintargetsdrug0.60
benchmark_ot_ad_answer_key:ALXdata_indataset_row0.00

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

Do SPM receptors undergo desensitization with chronic agonist treatment, prevent

pharmacology | 2026-04-11 | 0 hypotheses

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found